Showing results (61-70 of 124) with videos related to

Sort By:
Pageof 13
Diabetes|September 25, 2021
Contraction-Mediated Glucose Transport in Skeletal Muscle Is Regulated by a Framework of AMPK, TBC1D1/4, and Rac1Christian de Wendt, Lena Espelage, Samaneh Eickelschulte, et al.
Diabetes|October 18, 2014
Opposing effects of reduced kidney mass on liver and skeletal muscle insulin sensitivity in obese miceSiew Hung Chin, Flurin Item, Stephan Wueest, et al.
The Journal of Biological Chemistry|September 1, 2005
The elongated first fibronectin type III domain of collagen XIV is an inducer of quiescence and differentiation in fibroblasts and preadipocytesMartin Ruehl, Ulrike Erben, Detlef Schuppan, et al.
ACS Nano|October 30, 2018
Synthetic Cargo Internalization Receptor System for Nanoparticle Tracking of Individual Cell Populations by Fluorine Magnetic Resonance ImagingSebastian Temme, Paul Baran, Pascal Bouvain, et al.
Archives of Physiology and Biochemistry|March 1, 2014
Over-expression of PRAS40 enhances insulin sensitivity in skeletal muscleClaudia Wiza, Alexandra Chadt, Marcel Blumensatt, et al.
Endocrinology|December 30, 2006
Ablation of the cholesterol transporter adenosine triphosphate-binding cassette transporter G1 reduces adipose cell size and protects against diet-induced obesityJana Buchmann, Christoph Meyer, Susanne Neschen, et al.
Cardiovascular Diabetology|April 8, 2016
Cohort profile: the German Diabetes Study (GDS)Julia Szendroedi, Aaruni Saxena, Katharina S Weber, et al.
The Journal of Clinical Endocrinology and Metabolism|February 2, 2016
Specific Metabolic Profiles and Their Relationship to Insulin Resistance in Recent-Onset Type 1 and Type 2 DiabetesBirgit Knebel, Klaus Strassburger, Julia Szendroedi, et al.
Scientific Reports|March 19, 2020
Rhein, a novel Histone Deacetylase (HDAC) inhibitor with antifibrotic potency in human myocardial fibrosisDavid Monteiro Barbosa, Pia Fahlbusch, Daniella Herzfeld de Wiza, et al.
BMJ Open|February 4, 2022
BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathyGidon J Bönhof, Gundega Sipola, Alexander Strom, et al.
Pageof 13